PATENT CLAIM ANALYSIS

Application Number: 16214996
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-03
Patent Classification: ["514", "012000"]

Abstract:
The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.

Claim (Index 5):
A method as defined in  claim 4 , wherein said second coagulant agent is selected from the group consisting of Factor VIII, Factor IX, and Factor XIII.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 98.0
- Lexical Diversity: 1.25806
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12127917', '10196902', '10290814', '10287084', '10290591']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8555866617770578
- 35 USC 102 Novelty (BERT): 0.5942486841960599
- Combined Prediction Score: 0.829452864018958
- Mean Citation Score: 434.99349400000006
- Max Citation Score: 570.37994
- Similarity Product: 429.22222458891406

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test